SCHEMBL854852

SCHEMBL854852

CC(C)c1ccc(N(Cc2ccc(Cl)c(Cl)c2)C(=O)Nc2c(C(C)C)cccc2C(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 1/20 0.43
S1PR5 Q9H228 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
NR1H4 Q96RI1 1/20 0.40
NLRP3 Q96P20 1/20 0.39
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
SOAT2 O75908 1/20 0.37
SOAT1 P35610 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856560 0.90 SMN1; SMN2 (0.46) SMN1; SMN2NLRP3LMNAKMT2ASOAT2
SCHEMBL855085 0.88 SMN1; SMN2 (0.45) S1PR4S1PR5SMN1; SMN2KMT2A
SCHEMBL854382 0.85 SOAT1 (0.47) SMN1; SMN2NLRP3LMNAKMT2ASOAT2
SCHEMBL855945 0.85 SOAT2 (0.47) SMN1; SMN2NR1H4LMNAKMT2ASOAT2
SCHEMBL854986 0.84 SMN1; SMN2 (0.41) SMN1; SMN2NR1H4LMNA
SCHEMBL856005 0.84 SMN1; SMN2 (0.41) SMN1; SMN2LMNAKMT2ASOAT2SOAT1
SCHEMBL855314 0.83 LMNA (0.43) SMN1; SMN2LMNAKMT2ASOAT2SOAT1
SCHEMBL5049340 0.83 POLB (0.45) SMN1; SMN2POLBKMT2A
SCHEMBL856614 0.83 KMT2A (0.40) SMN1; SMN2NR1H4LMNAKMT2A
SCHEMBL856269 0.83 GAA (0.47) SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1308438-B9 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-28 EP claimed
EP-1308438-B1 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2010-10-20 EP claimed
US-7105567-B2 3-substituted urea derivatives and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-09-12 US claimed
US-20030207939-A1 Novel 3-substituted urea derivatives and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-11-06 US claimed
EP-1308438-A1 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-05-07 EP claimed
EP-1308438-B9 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-28 EP disclosed
EP-1308438-B1 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2010-10-20 EP disclosed
US-7105567-B2 3-substituted urea derivatives and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-09-12 US disclosed
US-20030207939-A1 Novel 3-substituted urea derivatives and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-11-06 US disclosed
EP-1308438-A1 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207939-A1 Novel 3-substituted urea derivatives and medicinal use thereof C5AR1, C5AR2, C3AR1 S1PR4 324/4885S1PR5 238/4885SMN1; SMN2 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.